While cancer therapies have advanced significantly in recent years, issues such as drug resistance and immune escape continue to pose major hurdles to achieving optimal clinical outcomes. These challenges are largely driven by a tumor-induced immunosuppressive microenvironment that prevents the immune system from effectively attacking cancer cells.
A primary driver of this suppressive environment is a population of cells known as myeloid-derived suppressor cells (MDSCs). Influenced by tumor-derived cytokines and chemokines, MDSCs help shield tumors from immune detection, making them a critical focus for understanding treatment resistance and developing better cancer therapies.
Source Attribution: Article content originally reported by Deng; Rongjun; Bai; Xiuyun; Yang; Jue; Ye; Wanting; Liu; Qiqiong; Xing; Ying; Yao; Yuxing; He; Xiaojuan; Lyu; Aiping; Yuanyan. Read original story coverage on Deng; Rongjun; Bai; Xiuyun; Yang; Jue; Ye; Wanting; Liu; Qiqiong; Xing; Ying; Yao; Yuxing; He; Xiaojuan; Lyu; Aiping; Yuanyan →
